WO2010130900A3 - Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25 - Google Patents

Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25 Download PDF

Info

Publication number
WO2010130900A3
WO2010130900A3 PCT/FR2010/000371 FR2010000371W WO2010130900A3 WO 2010130900 A3 WO2010130900 A3 WO 2010130900A3 FR 2010000371 W FR2010000371 W FR 2010000371W WO 2010130900 A3 WO2010130900 A3 WO 2010130900A3
Authority
WO
WIPO (PCT)
Prior art keywords
cdc25 phosphatase
phosphatase inhibitors
triaminopyrimidine
derivatives
triaminopyrimidine derivatives
Prior art date
Application number
PCT/FR2010/000371
Other languages
English (en)
Other versions
WO2010130900A2 (fr
Inventor
Anne-Marie Liberatore
Grégoire Prevost
Serge Auvin
Laetitia Brehu
Original Assignee
Ipsen Pharma S.A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0902352A external-priority patent/FR2945532A1/fr
Priority claimed from FR0902353A external-priority patent/FR2945530A1/fr
Application filed by Ipsen Pharma S.A.S. filed Critical Ipsen Pharma S.A.S.
Publication of WO2010130900A2 publication Critical patent/WO2010130900A2/fr
Publication of WO2010130900A3 publication Critical patent/WO2010130900A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a pour objet de nouveaux dérivés de triamino-pyrimidine de formule (I) dans laquelle Rl, R2, L, R3, R4a, R5a, R4b, R5b sont des variables. Ces produits ont une activité inhibitrice de phosphatases Cdc25. L'invention concerne également un procédé de synthèse de ces composés ainsi que des compositions thérapeutiques contenant ces produits et leur utilisation comme médicament.
PCT/FR2010/000371 2009-05-15 2010-05-12 Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25 WO2010130900A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0902352A FR2945532A1 (fr) 2009-05-15 2009-05-15 Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25
FR0902353A FR2945530A1 (fr) 2009-05-15 2009-05-15 Derives de tri-amino-pyridine comme inhibiteurs de phosphatases cdc25
FR0902352 2009-05-15
FR0902353 2009-05-15

Publications (2)

Publication Number Publication Date
WO2010130900A2 WO2010130900A2 (fr) 2010-11-18
WO2010130900A3 true WO2010130900A3 (fr) 2011-04-07

Family

ID=42358310

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2010/000371 WO2010130900A2 (fr) 2009-05-15 2010-05-12 Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25

Country Status (1)

Country Link
WO (1) WO2010130900A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026941A1 (fr) * 1995-03-02 1996-09-06 Pharmacia & Upjohn Company PYRIMIDO[4,5-b]INDOLES
US20060281712A1 (en) * 2005-06-14 2006-12-14 Chi-Feng Yen Pyrimidine compounds
WO2008005538A2 (fr) * 2006-07-05 2008-01-10 Exelixis, Inc. Procédés d'utilisation de modulateurs de kinase igf1r et abl
WO2008031556A2 (fr) * 2006-09-12 2008-03-20 Ucb Pharma, S.A. Nouveaux dérivés de la 2-amino-pyrimidine, procédés pour les préparer, compositions pharmaceutiques les contenant
FR2915747A1 (fr) * 2007-05-04 2008-11-07 Sod Conseils Rech Applic Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatase cdc25

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026941A1 (fr) * 1995-03-02 1996-09-06 Pharmacia & Upjohn Company PYRIMIDO[4,5-b]INDOLES
US20060281712A1 (en) * 2005-06-14 2006-12-14 Chi-Feng Yen Pyrimidine compounds
WO2008005538A2 (fr) * 2006-07-05 2008-01-10 Exelixis, Inc. Procédés d'utilisation de modulateurs de kinase igf1r et abl
WO2008031556A2 (fr) * 2006-09-12 2008-03-20 Ucb Pharma, S.A. Nouveaux dérivés de la 2-amino-pyrimidine, procédés pour les préparer, compositions pharmaceutiques les contenant
FR2915747A1 (fr) * 2007-05-04 2008-11-07 Sod Conseils Rech Applic Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatase cdc25

Also Published As

Publication number Publication date
WO2010130900A2 (fr) 2010-11-18

Similar Documents

Publication Publication Date Title
WO2011138751A3 (fr) Dérivés hétérocycliques destinés au traitement de maladies
UA110197C2 (ru) Соединения, эффективные как ингибиторы для ксантиноксидазы, процесса получения таких соединений и фармацевтической композиции, содержащей терапевтически эффективное количество таких соединений.
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
MX336381B (es) Boronatos como inhibidores de arginasa.
MY152048A (en) 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
AU2012204982A8 (en) 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors
WO2010093191A3 (fr) Nouveaux composés efficaces en tant qu'inhibiteurs de xanthine oxydase, leur procédé de préparation et composition pharmaceutique les contenant
WO2011033265A8 (fr) Composés pharmaceutiques
MY165087A (en) Neprilysin inhibitors
WO2008145688A3 (fr) Nouveaux composés
WO2008132139A3 (fr) Nouveaux dérivés hétérocycliques utiles pour le traitement des troubles du système nerveux central
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MX354476B (es) Inhibidores de neprilisina.
PH12015500211A1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
MY170935A (en) Neprilysin inhibitors
SG195319A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
JO3577B1 (ar) صيغ صيدلانية تشمل مشتقات 1-(بيتا-d- غلوكوبيرانوسيل) -2-ثينيل ميثيل بنزين كمثبطات sglt
GEP20146201B (en) Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors
WO2013057013A3 (fr) Dérivés d'alcools 1-phényl-2-pyridinylalkyliques utilisés comme inhibiteurs de phosphodiestérase
WO2009105969A8 (fr) Analogues d'épothilone, leurs compositions pharmaceutiques, leur utilisation et leurs préparations
NZ600453A (en) Inhibitors of akt activity
IN2012DN01292A (fr)
MX2010004604A (es) Derivados de pirazol como inhibidores de 5-lo.
WO2011047055A3 (fr) Nouveaux inhibiteurs de mek, utiles dans le traitement des maladies
MX2009011474A (es) Derivados de tri-amino-pirimidina como inhibidores de fosfatasa cdc25.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10723646

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10723646

Country of ref document: EP

Kind code of ref document: A2